-
Meeting Express . . . Navuliu mono-resistant: 240mg 30min is more convenient to administer!
Time of Update: 2020-07-18
The results of the checkmate 870 study confirmed the safety and reliability of the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients, mainly in Chinese population, with a fixed dose of 240 mg.
-
Antibody drug coupling new model! New company received about $100 million in financing to advance the HER2-plus solid tumor clinical trial.
Time of Update: 2020-07-18
in the press release, the new round of financing will support the continuous clinical development of its leading ISAC bdc-1001, which is currently used as a monotherapy for cancer expressing HER2; and support the company boltbody Gamma Expanded treatment pipeline platform.
-
2020 EHA Courier-Lymphoma Microclass: Changes in prognostic biomarker detection and treatment selection for Patients with CLL before and after the approval of the new drug.
Time of Update: 2020-07-18
Randomized studies have shown that new drugs can improve the prognosis of patients with CLL compared with chemotherapy and immunotherapy, especially for high-risk patients (such as del [17p], del [11q], IGHV without mutation, TP53 mutation).
-
Tumor control of new antibodies: Multiple PD-1/L1 monoanti-rebatch solid tumor new indications, ADC for cervical cancer to seek accelerated approval of the new observation of the medicine.
Time of Update: 2020-07-18
on December 19, 2019, FDA accelerated the approval of padcev (enfortumab vedotin ejfv), an ADC drug jointly developed by Seattle genetics and Astellas, to be used in patients with locally advanced or metastatic urothelial carcinoma who have received PD-1 / L1 inhibitors and platinum based chemotherapy.
-
The late gastric cancer after the line "every life", DS-8201 strong effect to overcome front-line drug resistance! New advances in drugs.
Time of Update: 2020-07-18
in the phase I study of ds-8201 (ds8201-a-j101), the efficacy of 5.4mg or 6.4mg/kg was evaluated in 44 patients with her positive gastric cancer or gastroesophageal junction cancer after trastuzumab treatment.
-
This effective method of preventing cervical cancer is only a quarter of the prevalence in China.
Time of Update: 2020-07-18
according to the research published in the weekly report of China Center for Disease Control and prevention, the screening rate of cervical cancer in Chinese women is still at a low level.
-
Nature Cancer: Chinese Academy of Sciences, nutrition institute Yu Huiyong and other discover the new mechanism to regulate liver cancer metabolism reprogramming.
Time of Update: 2020-07-18
on July 6, 2020, Yin Huiyong, Shanghai Institute of nutrition and health, Chinese Academy of Sciences, published online the latest research results entitled: aldolase B suppresses heparocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways.
-
Professor JCO, Professor Zhou Caixuan, wrote that the efficacy of the second-line treatment of HER2 mutation SSCLC can be forsomed.
Time of Update: 2020-07-18
References: caicun Zhou et al, pyrotinib in HER2 mutant advanced lung adenocarcinoma after platinum based chemotherapy: a multicenter, open label, single arm, phase II study.j Clin Oncol.
-
Nat Cancer . . . The Zhongbo team found important results in the regulation of intestinal infection immunity and tumor occurrence by ubiquitinase.
Time of Update: 2020-07-18
in the model of Citrobacter ratus or Salmonella typhimurium infection, the expression levels of inflammatory cytokines and antimicrobial peptides in serum and intestinal tissue of USP25 knockout mice were significantly increased, resulting in stronger immune response and better inhibition of the replication of intestinal infection bacteria.
-
The inhibition of human osteosarcoma cells through the Wnt/beta-Catenin pathway.
Time of Update: 2020-07-18
in addition, the luciferase activity in the evo treated group was significantly lower than that in the untreated group, and the expression level of the corresponding pathway protein also proved that Evo played an anti-cancer role in osteosarcoma cells by inhibiting Wnt / β - catenin signaling pathway.
-
The Zhongbo team at Wuhan University found an important function and mechanism for ubiquitinase to regulate the immune and tumor occurrence of intestinal infections.
Time of Update: 2020-07-18
the expression level of USP25 in colon tissue or colon epithelial cells induced by bacterial infection and DSS was significantly increased, which indicated that intestinal infection inhibited host anti infection immune response by up regulating the expression of USP25.
-
Nature Cancer: The Bell Wave team at Wuhan University has discovered the important functions and mechanisms of ubiquitinase that regulate sein infection immunity and tumor development.
Time of Update: 2020-07-18
in the model of Citrobacter ratus or Salmonella typhimurium infection, the expression levels of inflammatory cytokines and antimicrobial peptides in serum and intestinal tissue of USP25 knockout mice were significantly increased, resulting in stronger immune response and better inhibition of the replication of intestinal infection bacteria.
-
Express . . . Keytruda has been approved by the FDA for a first-line single drug for specific colorectal cancer patients, promising to change treatment patterns.
Time of Update: 2020-07-18
▎ the US FDA announced today that it has approved the extended indication of keytruda (pembrolizumab), a heavy-weight PD-1 inhibitor developed by MSD, as the first-line treatment for colorectal cancer patients with unresectable or metastatic microsatellite instability (MSI-H) or mismatch repair defect (dmmr).
-
Protein and Cell: The Zhejiang University Junxia team reveals the important mechanisms of gastrointestinal tumor targeting drug resistance.
Time of Update: 2020-07-18
in combination with targeted inhibition of ERBB3 and FGFR1 in tumor bearing mice, the research results showed that gastrointestinal cancer cells carrying e28g hot spot mutation ERBB3 were significantly tolerant to FGFR1 inhibitors through systemic TKIs tolerance screening.
-
Professor Wang Fenghua: 2020 CSCO gastric cancer diagnosis and treatment guidelines update disparate key points and research progress.
Time of Update: 2020-07-18
Artist2 is a phase III clinical study to evaluate the efficacy of S-1 vs Sox vs S-1 + oxaliplatin + radiotherapy (soxrt) for adjuvant treatment of stage II / III lymph node positive gastric cancer after D2 resection.
-
"The Lancet - Oncology" Hertje led the study: from the tumor registration to see the chinese cancer burden 40 years of change and prevention and control.
Time of Update: 2020-07-18
in the latest issue of Lancet Oncology, academician He Jie, director of China National Cancer Center and President of Cancer Hospital of Chinese Academy of Medical Sciences, published an important review, introduced the development milestone and current situation of China Cancer Registration Center, and analyzed the changes of cancer burden in China in recent 40 years from tumor registration data, and the impact on prevention and control.
-
Targeting B7-H3 mono-disresistance/ADC/CAR-T cells fully flowering, in which mono-anti products have started the market-to-market program, medical wheat new observation.
Time of Update: 2020-07-18
July 3, 2020 / emedclub news / - - y-mabs therapeutics, which focuses on the development and commercialization of new and antibody based cancer treatment products, has recently announced that according to the rolling review procedure (rolling) of FDA Review) has started to submit a biologicalproduct license application ("BLA") for omburtamab (monoclonal antibody targeting B7-H3) for the treatment of pediatric patients with neuroblastoma central nervous system / meningeal metastasis.
-
Oncolytics lysopas virus pioneer drug Pelareorep in conjunction with Merck/Pfizer anti-PD-L1 therapy phase II clinical completion of the first patient-administered medicine maesher.
Time of Update: 2020-07-18
this study (bracelet-1) is an open label, randomized phase II clinical trial conducted by oncolytics biotech of Canada and Merck of Germany KGaA) and Pfizer (Pfizer) to evaluate the antitumor effect of pelareorep combined with paclitaxel and avelumab (bavencio?) in the treatment of refractory metastatic breast cancer with HR + / HER2 endocrine therapy.
-
Osteosin reverses gastric cancer cisplatin resistance by blocking the miR196a-HOXB7-HER2 pathway.
Time of Update: 2020-07-18
cell proliferation test and monoclonal formation test were used to detect cell proliferation, flow cytometry was used to detect cell apoptosis, nude mice tumorigenesis test was used to detect the effect of drug on tumor growth, real-time fluorescent quantitative PCR and Western blot were used to detect the mRNA and protein levels of drug-resistant related pathway genes to explore mir-196a-5p Effect of hepsoralen on cisplatin resistance of gastric cancer and its molecular mechanism.
-
Three months after it was approved, the world's first ADC to treat triple-negative breast cancer has finally revealed the results of the phase 3 study.
Time of Update: 2020-07-18
July 8, 2020 / emedclub news / - April 22, 2020, antibody coupled drug (ADC drug) trodelvy (sacituzumab govitecan hziy) of immunomedics Co., Ltd, Immu-132) has been approved by FDA to treat patients with metastatic triple negative breast cancer (mtnbc) who have received at least two previous treatments.
